S&P 500   3,004.22 (+0.60%)
DOW   26,809.82 (+0.15%)
QQQ   193.21 (+0.79%)
AAPL   240.62 (+1.78%)
FB   189.30 (+1.86%)
MSFT   138.11 (+0.50%)
GOOGL   1,245.54 (+0.09%)
AMZN   1,782.75 (+1.44%)
CGC   20.37 (+0.79%)
NVDA   195.26 (+2.50%)
MU   45.22 (+4.03%)
BABA   172.80 (+2.17%)
GE   8.79 (-1.90%)
TSLA   253.46 (-1.36%)
AMD   32.12 (+3.71%)
T   38.30 (-0.44%)
F   9.05 (-2.58%)
BAC   31.07 (+2.34%)
DIS   130.25 (-0.49%)
S&P 500   3,004.22 (+0.60%)
DOW   26,809.82 (+0.15%)
QQQ   193.21 (+0.79%)
AAPL   240.62 (+1.78%)
FB   189.30 (+1.86%)
MSFT   138.11 (+0.50%)
GOOGL   1,245.54 (+0.09%)
AMZN   1,782.75 (+1.44%)
CGC   20.37 (+0.79%)
NVDA   195.26 (+2.50%)
MU   45.22 (+4.03%)
BABA   172.80 (+2.17%)
GE   8.79 (-1.90%)
TSLA   253.46 (-1.36%)
AMD   32.12 (+3.71%)
T   38.30 (-0.44%)
F   9.05 (-2.58%)
BAC   31.07 (+2.34%)
DIS   130.25 (-0.49%)
Log in

Xeris Pharmaceuticals News Headlines (NASDAQ:XERS)

$8.63
-0.38 (-4.22 %)
(As of 10/21/2019 02:49 PM ET)
Today's Range
$8.51
Now: $8.63
$9.06
50-Day Range
$7.61
MA: $9.76
$11.59
52-Week Range
$6.85
Now: $8.63
$25.49
Volume2,640 shs
Average Volume121,206 shs
Market Capitalization$232.92 million
P/E RatioN/A
Dividend YieldN/A
Beta-0.44

Headlines

Xeris Pharmaceuticals (NASDAQ XERS) News Headlines

Source:
DateHeadline
Steven Prestrelski Sells 27,700 Shares of Xeris Pharmaceuticals Inc (NASDAQ:XERS) StockSteven Prestrelski Sells 27,700 Shares of Xeris Pharmaceuticals Inc (NASDAQ:XERS) Stock
www.americanbankingnews.com - October 17 at 7:38 PM
Xeris Pharmaceuticals Appoints Mark Thierer to Board of DirectorsXeris Pharmaceuticals Appoints Mark Thierer to Board of Directors
finance.yahoo.com - October 1 at 8:07 AM
Xeris Pharmaceuticals Inc (NASDAQ:XERS) Short Interest Up 17.2% in SeptemberXeris Pharmaceuticals Inc (NASDAQ:XERS) Short Interest Up 17.2% in September
www.americanbankingnews.com - September 27 at 1:13 AM
FDA OKs Xeris Pharmas glucagon for severe low blood sugar in diabeticsFDA OKs Xeris Pharma's glucagon for severe low blood sugar in diabetics
seekingalpha.com - September 10 at 4:48 PM
Great News for Patients With Dangerously Low Blood SugarGreat News for Patients With Dangerously Low Blood Sugar
247wallst.com - September 10 at 4:48 PM
UPDATE 2-Xeris Pharma's low blood sugar treatment wins FDA approvalUPDATE 2-Xeris Pharma's low blood sugar treatment wins FDA approval
finance.yahoo.com - September 10 at 4:48 PM
Xeris Pharmaceuticals Receives U.S. FDA Approval for GVOKE™ (glucagon), the First Ready-to-use Stable Liquid Glucagon for Severe HypoglycemiaXeris Pharmaceuticals Receives U.S. FDA Approval for GVOKE™ (glucagon), the First Ready-to-use Stable Liquid Glucagon for Severe Hypoglycemia
finance.yahoo.com - September 10 at 11:38 AM
Xeris Pharmaceuticals Announces Expanded $85 Million Debt Facility With Oxford Finance and Silicon Valley BankXeris Pharmaceuticals Announces Expanded $85 Million Debt Facility With Oxford Finance and Silicon Valley Bank
finance.yahoo.com - September 10 at 11:38 AM
The Week Ahead In Biotech: Conference Presentations, IPO News Flow Take The SpotlightThe Week Ahead In Biotech: Conference Presentations, IPO News Flow Take The Spotlight
feeds.benzinga.com - September 8 at 12:40 PM
Xeris Pharmaceuticals (XERS) Presents At 2019 Wells Fargo Healthcare Conference - SlideshowXeris Pharmaceuticals (XERS) Presents At 2019 Wells Fargo Healthcare Conference - Slideshow
seekingalpha.com - September 7 at 8:53 AM
Xeris: Preparing For The Gvoke PDUFAXeris: Preparing For The Gvoke PDUFA
seekingalpha.com - September 7 at 8:53 AM
Have Insiders Been Buying Xeris Pharmaceuticals, Inc. (NASDAQ:XERS) Shares?Have Insiders Been Buying Xeris Pharmaceuticals, Inc. (NASDAQ:XERS) Shares?
finance.yahoo.com - September 4 at 4:00 PM
Xeris Pharmaceuticals to Present at Two September Healthcare ConferencesXeris Pharmaceuticals to Present at Two September Healthcare Conferences
finance.yahoo.com - August 29 at 9:04 PM
Xeris Pharmaceuticals EPS misses by $0.32, beats on revenueXeris Pharmaceuticals EPS misses by $0.32, beats on revenue
seekingalpha.com - August 6 at 9:12 PM
Xeris Pharmaceuticals Announces Second Quarter 2019 Financial Results and HighlightsXeris Pharmaceuticals Announces Second Quarter 2019 Financial Results and Highlights
finance.yahoo.com - August 6 at 9:12 PM
Xeris Pharmaceuticals, Inc. (XERS) Reports Q2 Loss, Tops Revenue EstimatesXeris Pharmaceuticals, Inc. (XERS) Reports Q2 Loss, Tops Revenue Estimates
finance.yahoo.com - August 6 at 9:12 PM
Xeris Pharmaceuticals, Inc. (XERS) May Report Negative Earnings: Know the Trend Ahead of Q2 ReleaseXeris Pharmaceuticals, Inc. (XERS) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
finance.yahoo.com - August 5 at 11:25 AM
Did Changing Sentiment Drive Xeris Pharmaceuticals's (NASDAQ:XERS) Share Price Down By 38%?Did Changing Sentiment Drive Xeris Pharmaceuticals's (NASDAQ:XERS) Share Price Down By 38%?
finance.yahoo.com - July 18 at 3:49 PM
Xeris Pharmaceuticals Doses First Patient in Phase 2 Trial Evaluating Its Developmental Ready-to-use Glucagon in Patients at Risk From Hypoglycemia Following Bariatric SurgeryXeris Pharmaceuticals Doses First Patient in Phase 2 Trial Evaluating Its Developmental Ready-to-use Glucagon in Patients at Risk From Hypoglycemia Following Bariatric Surgery
finance.yahoo.com - June 27 at 3:49 PM
XERIS PHARMACEUTICALS INCXERIS PHARMACEUTICALS INC
www.finanznachrichten.de - June 17 at 11:12 PM
Xeris reports positive trial results for RTU glucagon in hypoglycemiaXeris reports positive trial results for RTU glucagon in hypoglycemia
seekingalpha.com - June 17 at 12:48 PM
Xeris Pharmaceuticals Announces Additional Positive Outcomes from a Global Phase 3 Clinical Trial of Its Investigational Ready-to-Use GlucagonXeris Pharmaceuticals Announces Additional Positive Outcomes from a Global Phase 3 Clinical Trial of Its Investigational Ready-to-Use Glucagon
finance.yahoo.com - June 17 at 12:48 PM
Xeris: Gvoke PDUFA Gets Delayed And Creates Buying OpportunityXeris: Gvoke PDUFA Gets Delayed And Creates Buying Opportunity
seekingalpha.com - June 11 at 12:07 PM
FDA extends action date 90 days for Xeris Pharmas glucagon rescue penFDA extends action date 90 days for Xeris Pharma's glucagon rescue pen
seekingalpha.com - June 7 at 5:17 PM
Xeris Pharmaceuticals Receives Notification of PDUFA Date Extension for Gvoke™Xeris Pharmaceuticals Receives Notification of PDUFA Date Extension for Gvoke™
www.nasdaq.com - June 7 at 5:17 PM
Attention Biotech Investors: Mark Your Calendar For These June PDUFA DatesAttention Biotech Investors: Mark Your Calendar For These June PDUFA Dates
feeds.benzinga.com - May 31 at 1:54 PM
Can We See Significant Institutional Ownership On The Xeris Pharmaceuticals, Inc. (NASDAQ:XERS) Share Register?Can We See Significant Institutional Ownership On The Xeris Pharmaceuticals, Inc. (NASDAQ:XERS) Share Register?
finance.yahoo.com - May 25 at 11:22 AM
Xeris Pharmaceuticals Announces First Quarter 2019 Financial Results and Highlights Its PipelineXeris Pharmaceuticals Announces First Quarter 2019 Financial Results and Highlights Its Pipeline
finance.yahoo.com - May 10 at 11:59 AM
Xeris Pharmaceuticals Announces Results From a Phase 1 Study of Its Novel Formulation of DiazepamXeris Pharmaceuticals Announces Results From a Phase 1 Study of Its Novel Formulation of Diazepam
finance.yahoo.com - May 1 at 11:34 AM
Our Prognosis On XerisOur Prognosis On Xeris
seekingalpha.com - April 8 at 4:16 PM
Xeris up 1% on positive room-temp glucagon dataXeris up 1% on positive room-temp glucagon data
seekingalpha.com - March 25 at 12:13 PM
Xeris Pharmaceuticals Presents New Clinical and Economic Impact Data on Its Developmental Ready-to-Use GlucagonXeris Pharmaceuticals Presents New Clinical and Economic Impact Data on Its Developmental Ready-to-Use Glucagon
www.marketwatch.com - March 25 at 12:13 PM
Mid-stage study of Xeris Pharmas ready-to-use glucagon underwayMid-stage study of Xeris Pharma's ready-to-use glucagon underway
seekingalpha.com - March 15 at 12:22 PM
Xeris Pharmaceuticals Doses First Patient in Phase 2 Trial Evaluating Its Ready-to-Use Glucagon to Address Exercise-Induced HypoglycemiaXeris Pharmaceuticals Doses First Patient in Phase 2 Trial Evaluating Its Ready-to-Use Glucagon to Address Exercise-Induced Hypoglycemia
finance.yahoo.com - March 15 at 12:22 PM
Wednesday 3/13 Insider Buying Report: XERS, ATECWednesday 3/13 Insider Buying Report: XERS, ATEC
www.nasdaq.com - March 13 at 11:47 AM
How Many Insiders Bought Xeris Pharmaceuticals, Inc. (NASDAQ:XERS) Shares?How Many Insiders Bought Xeris Pharmaceuticals, Inc. (NASDAQ:XERS) Shares?
finance.yahoo.com - March 12 at 7:00 PM
Xeris: Looking For Entry Before PDUFAXeris: Looking For Entry Before PDUFA
seekingalpha.com - March 7 at 12:43 PM
Xeris Pharmaceuticals Announces Fourth Quarter and Full Year 2018 Financial Results and Highlights Pipeline ProgressXeris Pharmaceuticals Announces Fourth Quarter and Full Year 2018 Financial Results and Highlights Pipeline Progress
finance.yahoo.com - March 7 at 12:43 PM
Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
finance.yahoo.com - March 2 at 11:24 AM
Xeris Pharma down 9% premarket on stock offeringXeris Pharma down 9% premarket on stock offering
seekingalpha.com - February 14 at 11:45 AM
Xeris Pharmaceuticals Announces Pricing of Public Offering of Shares of Common StockXeris Pharmaceuticals Announces Pricing of Public Offering of Shares of Common Stock
finance.yahoo.com - February 14 at 11:45 AM
Mid-Day Market Update: Dow Rises Over 300 Points; Bristow Group Shares PlummetMid-Day Market Update: Dow Rises Over 300 Points; Bristow Group Shares Plummet
www.nasdaq.com - February 12 at 3:45 PM
Xeris Pharmaceuticals Inc.Xeris Pharmaceuticals Inc.
www.barrons.com - February 12 at 12:09 PM
Xeris Pharmaceuticals Announces Proposed Public Offering of Shares of Common StockXeris Pharmaceuticals Announces Proposed Public Offering of Shares of Common Stock
finance.yahoo.com - February 12 at 12:09 PM
The Daily Biotech Pulse: NASH Disappointment For Gilead, Xeris To Offer SharesThe Daily Biotech Pulse: NASH Disappointment For Gilead, Xeris To Offer Shares
finance.yahoo.com - February 12 at 12:09 PM
Nora Brennan Joins TELA Bio® as Chief Financial OfficerNora Brennan Joins TELA Bio® as Chief Financial Officer
www.bizjournals.com - January 2 at 10:47 AM
Xeris Pharmas liquid glucagon an Orphan Drug is Europe for rare insulin disorderXeris Pharma's liquid glucagon an Orphan Drug is Europe for rare insulin disorder
seekingalpha.com - December 20 at 3:31 PM
European Medicines Agency Grants Orphan Drug Designation for Xeris’ Investigational Ready-to-Use Glucagon for the Treatment of Non-Insulinoma Pancreatogenous Hypoglycaemia Syndrome (NIPHS)European Medicines Agency Grants Orphan Drug Designation for Xeris’ Investigational Ready-to-Use Glucagon for the Treatment of Non-Insulinoma Pancreatogenous Hypoglycaemia Syndrome (NIPHS)
finance.yahoo.com - December 20 at 10:36 AM
Xeris Pharmaceuticals Releases Additional Phase 3 Clinical Trial Data on Its Ready-to-Use Liquid Glucagon PenXeris Pharmaceuticals Releases Additional Phase 3 Clinical Trial Data on Its Ready-to-Use Liquid Glucagon Pen
www.bizjournals.com - November 12 at 3:23 PM
Xeris Pharmaceuticals Announces Third Quarter 2018 Financial Results and Highlights Pipeline ProgressXeris Pharmaceuticals Announces Third Quarter 2018 Financial Results and Highlights Pipeline Progress
finance.yahoo.com - November 7 at 8:46 AM
This page was last updated on 10/21/2019 by MarketBeat.com Staff

Featured Article: How Do Mutual Funds Work?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel